Statistics from Altmetric.com
The points below highlight changes in marketing authorisations (MAs) that may have a significant impact on veterinary surgeons’ prescribing decisions.
New marketing authorisations
New marketing authorisations relevant to veterinary surgeons in the UK that were issued or published in April 2020 are listed in Table 1.
Of those products listed, the VMD draws attention to:
• Aservo EquiHaler 30 mg/ml inhalation solution for horses. The first product containing ciclesonide, authorised in horses. Indicated for the alleviation of clinical signs of severe equine asthma (formerly known as recurrent airway obstruction, summer pasture associated recurrent airway obstruction).
• Hemosilate 125 mg/ml solution for injection. The first product containing etamsylate, authorised in cattle, sheep, goats, pigs, horses, dogs and cats. Indicated for the prevention and treatment of surgical, posttraumatic, obstetric and gynecological haemorrhages.
• Enrocat Flavour 25 mg/ml oral suspension for cats. An oral formulation containing the active substance enrofloxacin, authorised in cats for the treatment of single or mixed bacterial infections of the respiratory, digestive and urinary tract, otitis externa, skin and wound infections caused by the following enrofloxacin-sensitive Gram-positive and Gram-negative bacteria: Staphylococcus spp, Escherichia coli, Haemophilus spp and Pasteurella spp.
Table 1 also indicates …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.